Risk factor
Negligible price volatility
Profitability factor
Very strong margins and returns
About
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/E
Target Price
The average target price of SUNPHARMA.NS is 1957 and suggests 8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommen